Cadeddu Dessalvi, Christian
Pepe, Alessia
Penna, Claudia
Gimelli, Alessia
Madonna, Rosalinda
Mele, Donato
Monte, Ines
Novo, Giuseppina
Nugara, Cinzia
Zito, Concetta
Moslehi, Javid J
de Boer, Rudolf A
Lyon, Alexander R.
Tocchetti, Carlo Gabriele http://orcid.org/0000-0001-5983-688X
Mercuro, Giuseppe
Funding for this research was provided by:
Università degli Studi di Napoli Federico II (Ricerca di Ateneo)
Netherlands Heart Foundation (CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant 2017-21, CVON RED-CVD, grant 2017-11)
Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350)
Article History
First Online: 29 June 2019
Compliance with ethical standards
:
: Carlo Gabriele Tocchetti received speaking fees from Alere; Rudolf A de Boer: the UMCG, which employs RAdB, has received research grants and/or fees from AstraZeneca, Abbott, Bristol-Myers Squibb, Novartis, Roche, Trevena, and ThermoFisher GmbH. RAdB is a minority shareholder of scPharmaceuticals, Inc. RAdB received personal fees from MandalMed Inc., AstraZeneca, Novartis, Servier, and Vifor. Alexander R. Lyon has received speaker, advisory board or consultancy fees, and/or research grants from Pfizer, Novartis, Servier, Amgen, Clinigen Group, Takeda, Roche, Eisai Ltd., Eli Lily, and Boehringer Ingelheim. Javid Moslehi has served as a consultant/advisor for Novartis, Pfizer, Bristol-Myers Squibb, Takeda/Millennium, Ariad, Acceleron, Vertex, Incyte, Rgenix, Verastem, Pharmacyclics, StemCentRx, Heat Biologics, Daiichi-Sankyo, and Regeneron. All other authors have no conflicts of interest or financial ties to disclose.